ArticlePloS one2026
Integration of RNA-seq and scRNA-seq to investigate the role of cell cycle-related biomarkers in sepsis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a life-threatening organ dysfunction arising from a dysregulated host response to infection. Cell-cycle disturbance is increasingly recognized as a driver of sepsis-associated immune dysfunction. This study aimed to identify cell cycle-associated diagnostic biomarkers and clarify their roles in sepsis.
methodsTranscriptomic profiles from the Gene Expression Omnibus (GEO) database were analyzed to identify candidate genes by overlapping differentially expressed genes (DEGs) between sepsis and control samples with cell cycle-related genes (CCRGs). Biomarkers were subsequently screened via machine learning algorithms, followed by expression level validation and receiver operating characteristic (ROC) curve analysis. Furthermore, gene set enrichment analysis (GSEA), immune infiltration analysis, and drug prediction were performed.Finally, single-cell RNA sequencing (scRNA-seq) data were integrated for cell annotation and biomarker expression analysis, enabling the identification of key cells and the reconstruction of pseudotime trajectories.
resultsUPP1, DRAM1, GADD45A, and MAPK14 were selected as biomarkers and were significantly upregulated in sepsis samples (area under the curve (AUC) > 0.9). Additionally, GSEA revealed 65 pathways that were shared across all biomarkers, such as toll-like receptor signaling and antigen processing and presentation. Immune analysis revealed altered infiltration of 14 cell subsets in sepsis, including increased neutrophil numbers and decreased CD8+ T cell numbers. Drug prediction analysis identified 19 potential drugs, including doxorubicin hydrochloride and cisplatin with dual-targeting capacity. Finally, scRNA-seq confirmed CD16+ and CD14+ monocytes as key cells among the six cell types, with all biomarkers showing increasing expression trends during their differentiation.
conclusionThis study identified four cell cycle-associated biomarkers for sepsis and provided computational evidence linking them to sepsis-related pathways and monocyte differentiation. These findings may provide useful clues for future experimental validation and biomarker development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.